Eli Lilly’s latest $1.4 billion deal might come unglued

Off Biotech, biotechnology, Business, drug development, drug prices, drug pricing, finance, Health, Human Health, Life Sciences, Medicine, Pharma, Pharmaceuticals, Politics, research, Science and Research, The Readout, vaccines

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, everyone. Damian here with another multibillion-dollar deal, a word on the future of Sanofi, and a setback in one of medicine’s longest-running quests.

Read the rest…

Read Original Article: Eli Lilly’s latest $1.4 billion deal might come unglued »

About The Author